fbpx

Glaucoma Pharmacological Management

GLAUCOMA PHARMACOLOGICAL MANAGEMENT


GLAUCOMA

  • A condition characterised by progressive damage of optic nerve associated with raised intraocular pressure (>21mm/Hg).
  • Raising intraocular tension due to,
    • Excessive production 
    • Less drainage of aqueous humor.
  • Hence, anti-gluacomic drugs act by either,
    • Decreasing secretion (beta-blockers, alpha-2-agonists & carbonic anhydrase inhibitors).
    • Increaseing aqueous humor outflow (Miotics, Dipivefrine & prostoglandins).

CLASSIFICATION OF ANTI-GLAUCOMA DRUGS:

  • Topical Drops
  • Beta blockers
      • Eg. timolol, carteolol, betaxolol,levobunolol (may show add on effect so contraindicated with other beta-bocker) and metipranolol.
  • Adrenergic agonists
      • e.g. epinephrine, dipivefrin, brimonidine and apraclonidine
  • Prostaglandin analogue
      • e.g. latanoprost, bimatoprost ,unoprostone
  • Cholinergic agents
      • e.g. pilocarpine, carbachol,demecarium bromide and echothiophate iodide
  • Carbonic anhydrase inhibitors
      •  e.g. dorzolamide and brinzolamide
  • Systemic Drops
    • Carbonic anhydrase inhibitors.
    • e.g. acetazolamide and methazolamide
  • Osmotic agents
    • e.g. glycerine, mannitol and urea.

SPECIFIC MOA OF ANTI-GLAUCOMA AGENTS:

  • Beta blocker, adrenergic (alpha-2 agonist) & Carbonic anhydrase inhibitor – Decrease aqueous secretion.
  • Miotics – Increases trabecular outflow.
  • Prostaglandin – Increase trabecular & uveaoscleral outflow.

BETA-BLOCKERS:

  • First drug of choice for POAG.
  • Lower IOP by reducing aqueous secretion due to β2 receptors effect.
  • Topical β-blockers reduce aqueous formation by 24% to 48% in awake humans.
  • β-blockers are ineffective during sleep.
Drugs included: Timolol, betaxolol (Cardio-selective), levobetaxolol (Longest acting), levobunolol, carteolol, & metipranolol.

Mechanism of action:

  • By antagonizing catecholamines effect & causes reduction in aqueous secretion.
Indications:
  • Open angle glaucoma (DOC Timilol)
  • Angle closure Glaucoma
  • Secondary Glaucoma
  • Glaucoma in children

Contraindications:

  • Bronchial asthma
  • Severe COPD
  • Bradycardia 
  • Severe heart block
  • Overt cardiac failure
  • Children & infants.
Side effects: Blepharoconjunctivities.

Advantages of topical n-blockers (timolol) over miotics (Pilocarpine)

  • No change in pupil size (no miosis) → No fluctuation in I.O.T.
  • No induced myopia → Convenient once/twice daily applications
  • No ciliary spasm (no spasm of accomodation) → Few systemic side effects.

ADRENERGIC AGONIST:

  • Alpha 1 vasoconstriction of ciliary vessles decreased acqueous formation.
  • Alpha 2 ciliary epithelium: Decreased secretory activity
  • Drug used in refractory glaucoma.

Dipivefrine (adrenaline prodrug):

  • Decreasing aqueous formation by constricting ciliary blood vessels.
  • Increasing uveoscleral outflow by an increased prostaglandin synthesis.
  • Increasing trabecular outflow.

Epinephrine:

  • Nonselective α- and β-adrenergic agonist
  • Onset of action – 1 hr
  • Ocular hypotensive effect may last up to 72hours.
  • Black pigmentation on conjunctiva – Dueto oxidation product, adrenochrome.

Apraclonidine & Brimonidine:

  • Selective alpha-2 agonists.
  • Act by decreasing aqueous secretion.
  • Apraclonidine – Can cause lid retraction.
  • Brimonidine – CNS depression.

Side effects:

    • Stinging
    • Browache
    • Conjunctival hyperemia
    • Adenochrome deposits
    • Allergic lid reactions
  • Macular edema
  • Blepharoconjuntivitis
  • Systemic hypertension
  • Arrythmia
  • Drowsiness

Contraindications:

  • Severe Hypertension
  • Cardiac Diseases
  • Thyrotoxicosis

CHOLINERGIC DRUGS:

Mechanism of action:

  • Iris sphincter contraction → Constricts pupil (miosis)
  • Contraction of longitudinal fibers of ciliary muscle, producing scleral spur tension → Opening trabecular meshwork & facilitating aqueous outflow.
  • Contraction of circular fibers of ciliary muscle, relaxing zonular tension on lens equator → Accommodation

Classification:

Direct-acting:

  • Activate cholinergic receptors directly at neuroeffector junctions of iris sphincter muscle & ciliary body.

Indirect-acting (cholinesterase inhibitors):

  • Exert their cholinergic effects primarily by inhibiting cholinesterase, thereby making increased amounts of acetylcholine available at cholinergic receptors.

Indications:

  • Acute & chronic narrow angle glaucoma
  • Open angle glaucoma
  • Primary angle-closure glaucoma prophylaxis (until peripheral iridotomy can be performed).
  • Combination of pilocarpine & epinephrine may inhibit pigmented pupillary cyst

Contraindications:

  • Presence of cataract
  • Patients younger than 40 years of age
  • Neovascular and uveitic glaucoma
  • History of retinal detachment
  • Asthma or history of asthma
  • High myopia
  • Known hypersensitivity to the drug

PROSTAGLANDIN ANALOGUE:

  • Present naturally as mediators for ocular inflammatory response.
  • Pro-drugs – Converted to active compound by corneal esterases.
  • Pain in absolute glaucoma is best relieved by retrobulbar steroid injection.

MOA:

  • Increases uveoscleral outflow PG stimulates collagenase and metalloproteinase to degrade extracellular matrix between ciliary muscle bundles, which inturn leads to hydraulic resistance reduction to uveoscleral flow.

Indications:

  • Primary open angle glaucoma
  • Normal tension glaucoma
  • Chronic closed angle glaucoma
  • Pigment dispersion syndrome
  • Exfoliation glaucoma 

Contraindications:

  • Allergy
  • Pregnant and nursing mother
  • Children 
  • Uveiticglaucoma 
  • Immediate postoperative period
  • Pt. with healed or active  herpes simplex keratitis

Advantage:

  • Once daily dosing
  • Lack of cardiopulmonary side effects
  • Additivity to other anti glaucoma medications

CARBONIC ANHYDRASE INHIBITOR:

Mechanism:

  • Inhibit enzyme carbonic anhydrase.
    • Reducing aqueous humour formation.
    • Lower IOP.
  • Carbonic anhydrase is present in corneal endothelium so drugs that affect it impair its pump mechanism.
    • Thus contraindicated in pt. with compromised endothelium & who have gone keratoplasty.
  • In humans, aqueous flow rate normally decreases approximately 60% during sleep.
  • Acetazolamide has poor lipid solubility & corneal penetration, so not applied topically.
    • Reduces aqueous flow, an additional 24% below nocturnal flow rate. 
  • Timolol – No significant effect on aqueous flow in sleeping humans.
  • Systemic therapy is considered only last resort.

Contraindications:

  • Clinically significant liver disease
  • Severe chronic obstructive pulmonary disease
  • Certain secondary glaucoma
  • Renal disease, including kidney stones
  • Pregnancy
  • Pt. with known hypersensitivity to sulfonamide  

HYPEROSMOTIC AGENTS:

  • Osmotic agents are approved for short -term acute glaucoma management in adults.
    • Also used in reduction of vitreous volume prior to cataract surgery.
  • Acute angle closure glaucoma – First line treatment I.V. mannitol.
    • Mannitol must be given intravenously because it is not absorbed from GIT.

Mechanism of action:

Increase blood osmolality
Osmotic gradient between blood & vitreous
Water is drawn out of vitreous
 

Side effects:

  • Hematoma
  • Angina
  • Diuresis
  • Anuria
  • Ketoacidosis

Exam Important

  • Besides its properties of decreasing intraocular pressure, timolol is preferred in the treatment of glaucoma because it Produces no miosis
  • Drug of choice for open angle glaucoma Timolol
  • Acetazolamide s contra­indicated in sulfonamide hypersensitivity
  • Brimonidine can cause drowsiness
  • A patient with glaucoma is being treated with systemic beta blocker should not be given Levobunolol
  • Acute angle closure glaucoma first line treatment Iv mannitol
  • Drug used in refractory glaucoma Alpha agonist
  • Latanoprost used topically in glaucoma primarily acts by Increasing uveoscleral outflow
  • Main MOA brimonidine in glaucoma Decreased aqueous secretion
  • Drug kept as a last resort in the management of primary open angle glaucoma is Oral acetazolamide
  • Selective alpha 2 agoinst used in glaucoma is Brimonidine
  • Atropine should be avoided in angle closure glaucoma
  • Pain in absolute glaucoma is best relieved by Retrobulbar injection of steroid
  • Drug CONTRAINDICATED in glaucoma patients suffering from bronchial asthma is Timolol 
  • Combination of pilocarpine and epinephrine use in glaucoma treatment may inhibit Pigmented pupillary cyst
  • In primary angle-closure glaucoma pilocarpine lowers the intraocular pressure by its direct action on the Sphincter pupillae muscle
  • In primary open-angle glaucoma pilocarpine eye drops lowers the intraocular pressure by its direct action on the Longitudinal fibres of the ciliary muscle
  • In a hypertensive patient with glaucoma Dipivefrine is contraindicated
  • Treatment of malignant glaucoma includes Topical atropine, IV mannitol & Vitreous aspiration

 

Don’t Forget to Solve all the previous Year Question asked on GLAUCOMA PHARMACOLOGICAL MANAGEMENT

[ads id=”21882″]

Leave a Reply

Discover more from New

Subscribe now to keep reading and get access to the full archive.

Continue reading